Key result
Clarithromycin is linked to QTc prolongation and serious cardiac events, warranting caution with co-existing risk factors.
Why the study?
This paper examines whether the evidence linking clarithromycin to QTc prolongation is only theoretical.
Does clarithromycin increase the risk of QTc prolongation and serious cardiac events in patients?
Does clarithromycin increase the risk of QTc prolongation and serious cardiac events in patients?
Clarithromycin carries a clinically relevant risk of QTc prolongation and serious cardiac events beyond theoretical concerns, necessitating caution in patients with preexisting QTc risk factors.
Answers are grounded in this paper and cite their sources.
Clarithromycin may elevate QTc-related cardiac risk in vulnerable patients; leaves open precise incidence from controlled studies.
Evidence indicates that clarithromycin can cause QTc prolongation, with reported cases linking it to serious cardiac events. This suggests increased risk beyond purely theoretical bases, warranting cautious use, especially in patients with other QTc risk factors.
No takes yet. Share an insight, caveat, or question.
Tripdatabase (2026) studied this question. Clarithromycin is associated with QTc prolongation and serious cardiac events, warranting cautious use in patients with additional QTc risk factors.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: